Management of the Atomoxetine–Risperidone Interaction

Central Nervous System Monitoring

• Monitor patients for excessive sedation, somnolence, and cognitive impairment when atomoxetine and risperidone are co‑administered, because both agents have central nervous system effects. [1][2]

Pharmacogenetic Considerations

Genotyping Recommendation

• Perform CYP2D6 genotyping before starting the atomoxetine‑risperidone combination, as the test can identify patients who are at high risk for markedly increased atomoxetine exposure. 3

Phenoconversion Concept

• Co‑administration of risperidone (a CYP2D6 inhibitor) with atomoxetine can cause “phenoconversion,” whereby patients who are genetically extensive metabolizers function phenotypically as poor metabolizers, leading to substantially higher atomoxetine plasma levels. 3

Additive Inhibition with Other CYP2D6 Inhibitors

• Adding other CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, duloxetine) to the atomoxetine‑risperidone regimen produces additive inhibition of CYP2D6, further elevating atomoxetine concentrations and increasing the risk of adverse effects. 3

Alternative Antipsychotic Choices

• When atomoxetine therapy is required, select antipsychotics that exhibit minimal CYP2D6 inhibition to avoid the large increase in atomoxetine exposure seen with risperidone. [1][2]